Rémi Droller

Managing Partner, Kurma Partners

Mr. Droller joined Kurma Partners in 2010 and is in charge of investments in AM Pharma (The Netherlands), Orphazyme (Public, Denmark), Oxthera (Sweden), ImCheck (France), Stat Dx (sold to Qiagen, Spain), Zealand Pharma (Listed, Denmark), and Dynacure (France). Rémi started at CDC Innovation (now bpi France) from 2000 to 2003, later joining AGF Private Equity (now Idinvest Partners) where he developed the investment activity in the life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen), Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin), Vivacta (acquired by Novartis), IntegraGen (listed on Alternext), Onxeo (listed on Euronext).

Remi holds a Master in Molecular Biology (Paris VI) and Master in Finance and Innovation Management (Masternova – AgroPariTech).